Equities

Taysha Gene Therapies Inc

TSHA:NSQ

Taysha Gene Therapies Inc

Actions
  • Price (USD)2.15
  • Today's Change-0.03 / -1.38%
  • Shares traded1.44m
  • 1 Year change-30.65%
  • Beta0.3944
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

  • Revenue in USD (TTM)12.87m
  • Net income in USD-114.34m
  • Incorporated2020
  • Employees52.00
  • Location
    Taysha Gene Therapies Inc3000 Pegasus Park Drive, Suite 1430DALLAS 75247United StatesUSA
  • Phone+1 (214) 612-0000
  • Websitehttps://tayshagtx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Instil Bio Inc0.00-119.58m421.39m49.00--2.16-----18.39-18.390.0029.980.00----0.00-34.04---35.48--------------0.2958------30.06------
GH Research PLC-100.00bn-100.00bn421.43m49.00--2.12----------3.82----------------------------0.0038-------58.47------
Larimar Therapeutics Inc0.00-58.34m434.52m42.00--2.06-----1.11-1.110.003.310.00----0.00-33.44-42.22-36.41-47.14------------0.00-------4.51--8.71--
Grail Inc109.74m-2.88bn435.93m1.37k--0.1618--3.97-99.94-99.943.9186.80------81,894.77---47.45---48.5544.06---2,627.35-5,118.86----0.00--67.61--72.85---4.22--
ACELYRIN Inc0.00-299.80m437.16m130.00--0.7675-----3.06-3.060.005.710.00----0.00-40.33---43.71--------------0.00-------489.21------
iTeos Therapeutics Inc35.00m-108.14m442.46m157.00--0.6665--12.64-3.00-3.000.951718.180.0481--1.52222,929.90-14.865.84-15.557.02-----308.9622.09----0.000.00-95.29---216.54--68.45--
Taysha Gene Therapies Inc12.87m-114.34m446.78m52.00--4.03--34.71-0.8987-0.89870.06430.54060.0913----247,557.70-81.11---116.01-------888.18------0.2598--517.55--32.80------
C4 Therapeutics Inc29.38m-107.87m447.92m145.00--1.80--15.25-1.90-1.900.49443.590.0777--26.77202,606.90-28.53-25.91-33.00-29.45-----367.17-292.35----0.00---33.251.40-3.37---8.68--
Absci Corp3.25m-92.26m448.55m155.00--2.02--138.01-0.9331-0.93310.03271.950.0128--2.0320,967.74-36.20---40.23-------2,838.89-----129.460.0284---0.5046---5.40------
Fate Therapeutics Inc12.32m-175.72m455.51m181.00--1.15--36.98-1.71-1.710.11853.490.0221--6.3568,049.73-31.56-31.82-33.99-36.05-----1,426.67-359.33----0.00---34.0368.0542.88--21.72--
Verve Therapeutics Inc20.65m-192.65m456.13m255.00--0.8345--22.09-2.59-2.590.2756.460.032--8.0580,972.55-29.87---31.67-------933.03------0.00--505.77---27.12------
SAGE Therapeutics Inc97.24m-445.67m459.10m487.00--0.7291--4.72-7.41-7.411.6210.310.1093--6.75199,679.70-50.09-21.88-55.24-23.3095.4799.63-458.30-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Anavex Life Sciences Corp0.00-41.53m462.98m40.00--3.57-----0.5012-0.50120.001.530.00----0.00-27.75-40.04-30.03-43.97------------0.00------0.9857------
Contineum Therapeutics Inc-100.00bn-100.00bn473.31m31.00--2.18----------8.46----------------------------0.00------193.68------
Aura Biosciences Inc0.00-80.69m474.73m88.00--2.48-----1.79-1.790.003.860.00----0.00-39.26---41.21--------------0.00-------30.03------
Data as of Sep 18 2024. Currency figures normalised to Taysha Gene Therapies Inc's reporting currency: US Dollar USD

Institutional shareholders

52.42%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 202421.21m10.35%
RTW Investments LPas of 30 Jun 202418.80m9.17%
Avoro Capital Advisor LLCas of 30 Jun 202418.65m9.10%
RA Capital Management LPas of 30 Jun 202410.87m5.31%
BlackRock Fund Advisorsas of 30 Jun 202410.78m5.26%
Morgan Stanley & Co. LLCas of 30 Jun 20247.32m3.57%
The Vanguard Group, Inc.as of 30 Jun 20246.87m3.35%
Octagon Capital Advisors LPas of 30 Jun 20244.57m2.23%
Invus Public Equities Advisors LLCas of 30 Jun 20244.35m2.13%
Baker Bros. Advisors LPas of 30 Jun 20244.00m1.95%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.